M-phenyl diketone compound as well as preparation method and application thereof

By developing an isophenedione compound, using its hydrogen bond with 3CL hydrolase to form a stable complex, the problems of insufficient inhibitory activity and toxic side effects of existing anti-CoV drugs have been solved, and the effectiveness of 3CL hydrolase has been achieved Inhibiting and broad-spectrum antiviral effects.

CN119019482APending Publication Date: 2024-11-26SHIJIAZHUANG YILING PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310593731.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-24
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing anti-CoV drugs are difficult to effectively inhibit the activity of 3CL hydrolase, and there are variability problems, resulting in reduced efficacy, and traditional drugs may have toxic side effects on the human body.

Method used

A isophenedione compound was developed to form a stable complex by hydrogen bonding with 3CL hydrolase, inhibiting its activity, and to prepare the compound by multi-step isolation and purification methods to improve its antiviral potential.

Benefits of technology

This compound can form a stable interaction with 3CL hydrolase, significantly inhibit its activity, has broad-spectrum anti-coronavirus activity, reduces the risk of toxic side effects on the human body, and shows potential therapeutic effects in anti-SARS-CoV-2.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019482A_ABST
    Figure CN119019482A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of chemical medicines, and particularly relates to an m-phenyl diketone compound as well as a preparation method and application thereof. The m-phenylenedione compound is 3-C-beta-D-glucopyranosyl-5-methyl m-phenylenedione-6-O-beta-D-glucopyranoside, and can be prepared by performing water extraction and alcohol precipitation on rhizoma dryopteris crassirhizomae, extracting supernate by using ethyl acetate and n-butyl alcohol, performing macroporous resin column chromatography, performing silica gel column chromatography, performing liquid chromatographic separation and the like. The compound can form a stable complex with 3CL hydrolase, forms stable interaction with a binding pocket of the 3CL hydrolase, stabilizes amino acid residues in the binding pocket, has good inhibitory activity on the 3CL hydrolase, and has the potential of preparing anti-SARS-CoV-2 drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of chemical drugs, and specifically relates to an isophthalic acid dione compound and a preparation method and application thereof. Background Art

[0003] 3CL hydrolase, also known as 3C-like protease or main protease (Mpro), is the main protease found in coronaviruses and is also an enzyme necessary for the replication of the new coronavirus (SARS-CoV-2). After SARS-CoV-2 enters the cell, it cannot be subsequently translated and replicated without undergoing hydrolytic cleavage by 3CL hydrolase, and it cannot continue to produce progeny viruses. Inhibiting the activity of 3CL hydrolase can prevent the protein precursor from being cleaved and participating in the assembly to form mature virions, thereby preventing the virus from self-replication. 3CL hydrolase inhibitors have broad-spectrum anti-coronavirus activity. Even if SARS-CoV-2 mutates, drugs targeting this target may still be effective. At the same time, there is no 3CL homologous protein in the human body, so the risk of toxic side effects when taking 3CL hydrolase inhibitor drugs is relatively low. Therefore, drugs that act on this target have good application prospects, and obtaining more compounds that can be used to inhibit the activity of 3CL hydrolases is of great significance for the development of anti-SARS-CoV-2 drugs and the treatment of diseases caused by it. Summary of the invention

[0004] In response to the above problems, the present invention provides an isophthalic acid dione compound and a preparation method and application thereof. The compound can stably bind to the 3CL hydrolase target, has good inhibitory activity on 3CL hydrolase, and has the potential to become an active ingredient in anti-new coronavirus drugs.

[0005] In order to achieve the above-mentioned purpose of the invention, the embodiment of the present invention adopts the following technical solutions:

[0006] In a first aspect, the present invention provides an isophthalic acid compound, the structural formula of which is shown in Formula I:

[0007]

[0008] Molecular dynamics simulation shows that the above-mentioned isophthalic acid dione compound provided by the present invention can form a stable complex with 3CL hydrolase through hydrogen bonding, and the structure of the sugar ring in the compound and the amino acid residues Thr190 and Arg188 play an important role in the formation of hydrogen bonding. The stability of the complex is comparable to other drugs that currently work by inhibiting 3CL hydrolase. In addition, the compound can form a stable interaction with the binding pocket of 3CL hydrolase and stabilize the amino acid residues therein. Activity evaluation experiments have found that the compound has good inhibitory activity for 3CL hydrolase.

[0009] Therefore, the isophthalic acid dione compound provided by the present invention has the potential to prepare anti-SARS-CoV-2 drugs. The compound is a new compound that has not been reported yet, and provides a new active ingredient for the design of anti-SARS-CoV-2 drugs.

[0010] In a second aspect, the present invention also provides a method for preparing the above-mentioned isophthalic acid dione compound, comprising the following steps:

[0011] Step A, extracting the Rhizoma Cynomorii with water, adding ethanol to the obtained water extract, separating the supernatant after static precipitation, removing alcohol from the supernatant, extracting with ethyl acetate and n-butanol, and collecting the aqueous phase;

[0012] Step B, separating the aqueous phase by column chromatography using a macroporous resin column: eluting with water and 5-95% v / v ethanol in sequence, collecting the eluate obtained by eluting with 5-95% v / v ethanol, and concentrating it into a dry paste to obtain a first dry paste;

[0013] Step C, dissolving the first dry paste with an organic solvent, and separating it by column chromatography using a silica gel column: eluting with ethyl acetate, ethanol or a mixture of the two, collecting the obtained eluate, and concentrating it into a dry paste to obtain a second dry paste;

[0014] Step D: Separate the second dry paste by reverse medium pressure preparative chromatography using reverse phase silica gel: elute with 5-15% v / v methanol, 20-30% v / v methanol, and 35-50% v / v methanol in sequence, collect the eluate obtained by eluting with 35-50% v / v methanol, and concentrate to obtain a crude extract containing the isophthalic acid dione compound.

[0015] The invention can obtain a crude extract containing the isophthalic acid dione compound by extracting the rosmarinus officinalis with ethanol, extracting with ethyl acetate and n-butanol, and then gradually separating the extract with the above separation process.

[0016] In combination with the first aspect, in steps B, C, and D, the amount of each eluent used can be selected to be 1 to 10 column volumes.

[0017] In combination with the first aspect, the concentration of ethanol in step B is preferably 20% v / v. When elution is performed with ethanol at this concentration, the amount of the eluent used can be 5 column volumes.

[0018] In combination with the first aspect, in step B, the macroporous resin in the macroporous resin column may be AB-8 resin.

[0019] In combination with the first aspect, the organic solvent used to dissolve the first dry paste in step C can be selected from methanol, dichloromethane or a mixture of the two. After the first dry paste is dissolved in the organic solvent, it is mixed with 200-300 mesh silica gel at a mass ratio of 1:3-1, and then the solvent is evaporated to dryness, and added to a silica gel column filled with 200-300 mesh silica gel (equivalent to 5-50 times the weight of the dry paste), and column chromatography separation can be performed.

[0020] In combination with the first aspect, step C preferably uses ethyl acetate for elution, then ethyl acetate-ethanol with a volume ratio of 9:1, and then ethyl acetate-ethanol with a volume ratio of 8:2, and the eluate obtained by eluting with ethyl acetate-ethanol with a volume ratio of 8:2 is collected and concentrated into a dry paste to obtain a second dry paste. When eluting with this operation, the amount of ethyl acetate and ethyl acetate-ethanol can be selected to be 5 column volumes.

[0021] In combination with the first aspect, the preparation method further comprises dissolving the crude extract with a methanol aqueous solution, separating by semi-preparative high performance liquid chromatography, wherein the mobile phase of the semi-preparative high performance liquid chromatography is 5% to 95% v / v acetonitrile aqueous solution-0 to 0.5% v / v formic acid aqueous solution in a volume ratio of 1.3:8.7, and isocratic elution. The eluted fractions are collected according to the peak time of the compound to obtain the compound monomer.

[0022] The concentration of the methanol aqueous solution for dissolving the crude extract is not limited, as long as it can dissolve the crude extract. Exemplarily, the concentration of the methanol aqueous solution is 45-55% v / v.

[0023] Preferably, the chromatographic column of the semi-preparative high performance liquid chromatography is octadecyl bonded silica gel, preferably Waters Xterra ODB, with specifications of 19×250 mm, 10 μm.

[0024] Preferably, the column temperature of the semi-preparative HPLC is 25-35°C, more preferably 30°C.

[0025] Preferably, the flow rate of the semi-preparative HPLC method is 8 to 12 mL / min, more preferably 10 mL / min.

[0026] In a third aspect, the present invention also provides the use of the above-mentioned isophthalic acid dione compounds in the preparation of 3CL hydrolase inhibitors.

[0027] In a fourth aspect, the present invention also provides the use of the above-mentioned isophthalic acid dione compounds in the preparation of anti-coronavirus drugs.

[0028] Experimental verification showed that the compound can stably bind to 3CL hydrolase, has good inhibitory activity against 3CL hydrolase, and has the potential to resist coronavirus, so it can be used to prepare anti-coronavirus drugs.

[0029] In combination with the fourth aspect, the anti-coronavirus drug is an anti-severe acute respiratory syndrome coronavirus type 2 virus drug. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 is the IR spectrum of compound A in Example 1 of the present invention;

[0031] Figure 2 is the HR-ESI-MS spectrum of compound A in Example 1 of the present invention;

[0032] Figure 3 is the compound A in Example 1 of the present invention 1 H--NMR spectrum;

[0033] Figure 4 is the compound A in Example 1 of the present invention 13 C-NMR spectrum;

[0034] Figure 5 is the HSQC spectrum of compound A in Example 1 of the present invention;

[0035] Figure 6 is the HMBC spectrum of compound A in Example 1 of the present invention;

[0036] Figure 7 is a gas chromatogram of compound A in Example 1 of the present invention;

[0037] Figure 8 is the structure and key HMBC of compound A in Example 1 of the present invention;

[0038] Fig. 9 is the fluctuation of the root mean square fluctuation (RMSF) value of the amino backbone atoms in the compound-protein complex in Example 6 of the present invention;

[0039] Fig.10 This is the last conformation of the complex of compound A and 3CL hydrolase in Example 6 of the present invention after stabilization for 100 nanoseconds in molecular dynamics simulation. DETAILED DESCRIPTION

[0040] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0041] SARS-CoV-2 is the main pathogen that causes COVID-19. The nucleic acid sequence variation of the virus may lead to antigenic drift, thereby allowing the virus to evade the host's immune response and affect the efficacy of the vaccine. The embodiment of the present invention provides a isophthalic acid compound (3-C-β-D-pyranose glucopyranosyl-5-methyl isophthalic acid-6-O-β-D-glucopyranoside), the structural formula of which is shown in Formula I:

[0042]

[0043] 3CL hydrolase is an enzyme necessary for the replication of SARS-CoV-2. Inhibiting the activity of 3CL hydrolase can prevent the virus from self-replication. In addition, 3CL hydrolase inhibitors have broad-spectrum anti-coronavirus activity and high safety, and can be used as an important target for screening antiviral drugs. Molecular docking results show that the compound can form a stable complex with 3CL hydrolase; molecular dynamics studies have shown that the compound can form a stable interaction with the binding pocket of 3CL hydrolase and stabilize the amino acid residues therein; activity evaluation experiments have shown that the compound has good inhibitory activity against 3CL hydrolase. Therefore, the compound has the potential to resist SARS-CoV-2 and is expected to become a new active ingredient for antiviral drugs.

[0044] The present invention also provides a method for preparing the compound, comprising the following steps:

[0045] Step A, extracting the Rhizoma Cynomorii with water, adding ethanol to the obtained water extract, separating the supernatant after static precipitation, removing alcohol from the supernatant, extracting with ethyl acetate and n-butanol, and collecting the aqueous phase;

[0046] Step B, separating the aqueous phase by column chromatography using a macroporous resin column: eluting with water and 5-95% v / v ethanol in sequence, collecting the eluate obtained by eluting with 5-95% v / v ethanol, and concentrating it into a dry paste to obtain a first dry paste;

[0047] Step C, dissolving the first dry paste with an organic solvent, and separating it by column chromatography using a silica gel column: eluting with ethyl acetate, ethanol or a mixture of the two, collecting the obtained eluate, and concentrating it into a dry paste to obtain a second dry paste;

[0048] Step D: Separate the second dry paste by reverse medium pressure preparative chromatography using reverse phase silica gel: elute with 5-15% v / v methanol, 20-30% v / v methanol, and 35-50% v / v methanol in sequence, collect the eluate obtained by eluting with 35-50% v / v methanol, and concentrate to obtain a crude extract containing the above-mentioned isophthalic acid compounds.

[0049] In the above preparation method, the crude extract obtained in step D is dissolved in methanol aqueous solution and separated by preparative high performance liquid chromatography to obtain the monomer of the compound. The mobile phase preferably uses 5% to 95% v / v acetonitrile aqueous solution-0 to 0.5% v / v formic acid aqueous solution in a volume ratio of 1.3:8.7, and the eluted fraction is collected according to the peak time of the compound. The chromatographic column preferably uses octadecyl bonded silica gel, such as Waters Xterra ODB (19×250mm, 10μm). The column temperature is preferably 25 to 35°C. The flow rate is preferably 8 to 12mL / min.

[0050] In order to obtain a better separation effect and reduce the loss of the target product at the same time, the concentration of ethanol in step B is preferably 20% v / v, and step C is preferably eluted with ethyl acetate first, then eluted with ethyl acetate-ethanol with a volume ratio of 9:1, and then eluted with ethyl acetate-ethanol with a volume ratio of 8:2, and the eluate obtained by eluting with ethyl acetate-ethanol with a volume ratio of 8:2 is collected.

[0051] The scheme of the present invention is described below through specific embodiments.

[0052] Example 1

[0053] This embodiment provides a 3-C-β-D-pyranose glucopyranoside compound, 5-methyl-3-C-β-D-glucopyranoside, and a preparation method thereof.

[0054] The preparation method of compound A specifically comprises the following steps:

[0055] 1. Preparation of crude extract

[0056] Step A, add 450L of water to 45kg of Mianma Guanzhong and reflux extract for 3 times, each time for 1 hour. Combine the extracts, concentrate under reduced pressure to a specific gravity of 1.10-1.20, add ethanol to a mass concentration of 80%, stand at 4℃ for 24 hours, filter, and take the supernatant. Concentrate the supernatant under reduced pressure until there is no alcohol taste, add water to make the volume 20L, extract with equal volumes of ethyl acetate and n-butanol three times respectively, and then take the aqueous solution;

[0057] Step B, the aqueous solution was fixed to 180 L, and separated using an AB-8 resin column (resin dosage 90 kg), and the separation process was as follows: washing with 5 BV of water and eluting with 20% v / v ethanol, collecting the 20% v / v ethanol eluate (5 BV), and removing the solvent under reduced pressure to obtain a dry paste (first dry paste);

[0058] Step C. Separate the first dry paste obtained in step B using a silica gel (200-300 mesh) column. The separation process is as follows: dissolve the first dry paste in methanol, mix it with silica gel in a mass ratio of 1:2, then evaporate the solvent to dryness, add it to a silica gel column filled with silica gel (equivalent to 20 times the weight of the dry paste), first elute with 5BV ethyl acetate, then elute with 5BV ethyl acetate-ethanol (9:1, v / v), and then elute with 5BV ethyl acetate-ethanol (8:2, v / v), collect the ethyl acetate-ethanol (8:2, v / v) eluate, remove the solvent under reduced pressure, and obtain a dry paste (the second dry paste).

[0059] Step D: Dissolve the second dry paste obtained in step C with methanol, add an equal amount of reversed-phase silica gel (YMC GEL, ODS-AQ-HG, S-50 μm) and mix the sample. After evaporating the solvent, separate the sample by reversed-phase medium-pressure preparative chromatography (filler: YMC GEL, ODS-AQ-HG, S-50 μm; chromatographic column specification: 49×460 mm), and elute with 10% v / v methanol for 5VB, 25% v / v methanol for 5BV, and 40% v / v methanol for 5BV in sequence. Collect the 40% v / v methanol eluate, and remove the solvent under reduced pressure to obtain a crude extract.

[0060] 2. Monomer preparation

[0061] The crude extract was dissolved in 50% v / v methanol aqueous solution, filtered and injected into Waters 1525 semi-preparative liquid chromatograph. The chromatographic conditions were:

[0062] Chromatographic column model: Waters Xterra ODB (19×250mm, 10μm); mobile phase is 50% v / v ACN aqueous solution-0.2% v / v formic acid aqueous solution (1.3:8.7); flow rate 10mL / min; detection wavelength: 210nm, 280nm; column temperature: 30℃; injection volume: 20μl. The results show that under this chromatographic condition, the chromatographic peak separation is good and can be used for preparation and purification. The peak with a retention time of about 14min (the collection time in this embodiment is 13-15min) was collected, and the solvent was recovered under reduced pressure to obtain 15mg of compound A with a purity of >98%.

[0063] 3. Structural identification of compound A

[0064] The chemical structure of compound A was characterized by infrared spectroscopy (IR), mass spectroscopy (MS) and nuclear magnetic resonance (NMR).

[0065] The test data are as follows: IR (KBr) λ max :3280,2880,2103,1607,1423,1361,1275,1179,1128,1019,893,849,798,647,608,566cm -1;HR-TOF / MS: m / z 507.1729[M+H] + (The calculated value is 507.1714); 1 H-NMR (600 MHz, DMSO-d4) and 13 C-NMR (150 MHz, DMSO-d4) data are shown in Table 1. 1 H-NMR and 13 The C-NMR signals were completely assigned by a combination of HSQC and HMBC.

[0066] IR spectrum, HR-ESI-MS spectrum, 1 H--NMR spectrum, 13 The C-NMR spectrum, HSQC spectrum, HMBC spectrum and gas chromatogram are shown in Figure 1 to Figure 7 shown.

[0067] Table 1 Compound A in 1 H-NMR and 13 C-NMR spectral data (DMSO-d6)

[0068]

[0069] 4. Experimental Results

[0070] The obtained compound A is a light yellow powder, and its molecular formula is C 21 H 30 O 14 . Infrared spectra show that hydroxyl (3280cm -1 ), keto carbonyl (1608cm -1 ) and glycosidic bonds (1000-1130cm -1 ) characteristic band. 13 The C-NMR spectrum showed 21 carbon signals attributable to an aromatic ring fragment and two hexose residues. The NMR spectrum (Table 1) showed that at δ H 4.69 (1H, d, J = 7.7 Hz, H-1' and δ C 104.5, C-1′) and 5.10 (1H, d, J=8.9 Hz, H-1″ and δ C 75.7C-1〃) has two anomeric protons, at δ H 2.65 (3H, s, H-9 and δ C 33.2, C-8) and δ C There is an acetyl group at 204.5 (C-7), H 2.08 (3H, s, H-10 and δ C 8.9C-9) has a methyl group at δ HThere are two hydroxyl protons at 13.20 (OH, brs, C-2) and 9.44 (OH, brs, C-5). C 111.0 (C-1), 159.4 (C-2), 108.2 (C-3), 161.3 (C-4), 110.2 (C-5) and 157.5 (C-6) 13 The C-NMR carbon signal indicated the presence of an aromatic ring fragment. These NMR data indicate that compound A is a phenolic glycoside containing two sugar fragments. The absolute configuration of the glucosyl fragments was determined as follows: (1) O-glucosyl fragment: Compound A was hydrolyzed with HCl to obtain D-glucose, which was identified by gas chromatography (GC); the absolute configuration of the O-glucosyl fragment at C-3 was determined to be D-form; (2) C-glucosyl fragment: By comparing and analyzing the C-glucoside NMR data in the literature, the glucose fragments were connected by a carbon glycosidic bond at the C-6 position; the absolute configuration of the C-glucosyl fragment at C-6 was inferred to be D-type, because most C-glucosides found in plants are D-type. The configuration of the anomeric carbon of the two glucosyl fragments was determined to be β by the J values ​​at C-1′ and C″. By δ H 4.69(H-1′) and δ C 108.2(C-3),δ H 5.10(H-1″) and δ C The HMBC correlation between 157.5 (C-6) and 157.5 (C-6) determined the positions of the glucopyranosyl fragments attached to C-3 and C-6 of the aglycone; H 2.65(H-8) and δ C 204.5 (C-7) and δ H 2.68 (H-8) and δ C The position of the acetyl fragment attached to C-1 of the aglycone was determined by HMBC correlation between 1:111.0 (C-1).

[0071] Compound A (2.0 mg) was dissolved in 2% HCl (2 mL) and heated at 70 ° C for 12 h. After extraction with EtOAc (3 × 2 mL) to remove the aglycone, the aqueous layer was evaporated to provide a neutral residue. The dried sugar residue was diluted in anhydrous pyridine (1 mL), to which L-cysteine ​​methyl ester hydrochloride (2 mg) was added. The mixture was stirred at 60 ° C for 2 hours and then treated with N-trimethylsilyl imidazole (0.2 mL). The mixture was then heated to dryness at 60 ° C and heated for another 2 hours. The dried reactant was distributed three times between n-hexane (2 mL) and H2O (2 mL). The n-hexane layer was concentrated (1 mL) and subjected to GC analysis (column: Agilent HP-5, 30 m×0.25 mm×0.25 μm, Dikma; detector: FID; detector temperature: 280°C; injector temperature: 250°C; carrier: N2; programming temperature: from 200°C to 280°C in 2 minutes, and maintaining the final temperature for 30 minutes). The obtained gas chromatogram is shown in FIG. Figure 7 shown.

[0072] Based on these observations, the structure of compound A was identified as 3-C-β-D-glucopyranosyl-5-methylphloroacetophenone-6-O-β-D-glucopyranoside (structure and key HMBC as Figure 8 shown).

[0073] Example 2

[0074] This embodiment provides a 3-C-β-D-pyranose glucopyranoside compound, 5-methyl-3-C-β-D-glucopyranoside, and a preparation method thereof.

[0075] The preparation method of compound A specifically comprises the following steps:

[0076] 1. Preparation of crude extract

[0077] Step A, add 450L of water to 45kg of Mianma Guanzhong and reflux extract for 3 times, each time for 1 hour. Combine the extracts, concentrate under reduced pressure to a specific gravity of 1.10-1.20, add ethanol to a mass concentration of 80%, stand at 4℃ for 24 hours, filter, and take the supernatant. Concentrate the supernatant under reduced pressure until there is no alcohol taste, add water to make the volume 20L, extract with equal volumes of ethyl acetate and n-butanol three times respectively, and then take the aqueous solution;

[0078] Step B, the aqueous solution was fixed to 180 L, and separated using an AB-8 resin column (resin dosage 90 kg), and the separation process was as follows: washing with 5 BV of water and eluting with 55% v / v ethanol, collecting 55% v / v ethanol eluate (6 BV), and removing the solvent under reduced pressure to obtain a dry paste (first dry paste);

[0079] Step C. Separate the first dry paste obtained in step B using a silica gel (200-300 mesh) column. The separation process is as follows: dissolve the first dry paste in methanol, mix it with silica gel in a mass ratio of 1:2.5, and then evaporate the solvent to dryness. Add it to a silica gel column filled with silica gel (equivalent to 25 times the weight of the dry paste), first elute with 4BV of ethyl acetate, then elute with 6BV of ethanol, collect the ethanol eluate, and remove the solvent under reduced pressure to obtain a dry paste (the second dry paste).

[0080] Step D: Dissolve the second dry paste obtained in step C with methanol, add an equal amount of reversed-phase silica gel (YMC GEL, ODS-AQ-HG, S-50 μm) and mix the sample. After evaporating the solvent, separate the sample by reversed-phase medium-pressure preparative chromatography (filler: YMC GEL, ODS-AQ-HG, S-50 μm; chromatographic column specification: 49×460 mm), and elute with 5% v / v methanol 4VB, 25% v / v methanol 4BV, and 45% v / v methanol 6BV in sequence. Collect the 45% v / v methanol eluate, and remove the solvent under reduced pressure to obtain a crude extract.

[0081] 2. Monomer preparation

[0082] The crude extract was dissolved in 45% v / v methanol aqueous solution, filtered and injected into Waters 1525 semi-preparative liquid chromatograph. The chromatographic conditions were:

[0083] Chromatographic column model: Waters Xterra ODB (19×250mm, 10μm); mobile phase is 10% v / v ACN aqueous solution-0.3% v / v formic acid aqueous solution (1.3:8.7); flow rate 10mL / min; detection wavelength: 210nm, 280nm; column temperature: 30℃; injection volume: 20μl. The results show that under this chromatographic condition, the chromatographic peak separation is good and can be used for preparation and purification. The eluent was collected at the peak time of compound A, and the solvent was recovered under reduced pressure to obtain 9mg compound A with a purity of >98%.

[0084] Example 3

[0085] This embodiment provides a 3-C-β-D-pyranose glucopyranoside compound, 5-methyl-3-C-β-D-glucopyranoside, and a preparation method thereof.

[0086] The preparation method of compound A specifically comprises the following steps:

[0087] 1. Preparation of crude extract

[0088] Step A, add 450L of water to 45kg of Mianma Guanzhong and reflux extract for 3 times, each time for 1 hour. Combine the extracts, concentrate under reduced pressure to a specific gravity of 1.10-1.20, add ethanol to a mass concentration of 80%, stand at 4℃ for 24 hours, filter, and take the supernatant. Concentrate the supernatant under reduced pressure until there is no alcohol taste, add water to make the volume 20L, extract with equal volumes of ethyl acetate and n-butanol three times respectively, and then take the aqueous solution;

[0089] Step B, the aqueous solution was fixed to 180L, and separated using an AB-8 resin column (resin dosage 90kg), and the separation process was as follows: washing with 5BV of water and then eluting with 75% v / v ethanol, collecting 75% v / v ethanol eluate (4BV), and removing the solvent under reduced pressure to obtain a dry paste (first dry paste);

[0090] Step C. Separate the first dry paste obtained in step B using a silica gel (200-300 mesh) column. The separation process is as follows: dissolve the first dry paste in methanol, mix it with silica gel in a mass ratio of 1:1.5, evaporate the solvent to dryness, add it to a silica gel column filled with silica gel (equivalent to 18 times the weight of the dry paste), first elute with 5BV of ethyl acetate, then elute with 7BV of ethyl acetate-ethanol (8:2, v / v), collect the ethyl acetate-ethanol (8:2, v / v) eluate, remove the solvent under reduced pressure, and obtain a dry paste (the second dry paste).

[0091] Step D: Dissolve the second dry paste obtained in step C with methanol, add an equal amount of reversed-phase silica gel (YMC GEL, ODS-AQ-HG, S-50 μm) and mix the sample. After evaporating the solvent, separate the sample by reversed-phase medium-pressure preparative chromatography (filler: YMC GEL, ODS-AQ-HG, S-50 μm; chromatographic column specification: 49×460 mm), and elute with 10% v / v methanol 4VB, 20% v / v methanol 6BV, and 40% v / v methanol 6BV in sequence. Collect the 40% v / v methanol eluate, and remove the solvent under reduced pressure to obtain a crude extract.

[0092] 2. Monomer preparation

[0093] The crude extract was dissolved in 55% v / v methanol aqueous solution, filtered and injected into Waters 1525 semi-preparative liquid chromatograph. The chromatographic conditions were:

[0094] Chromatographic column model: Waters Xterra ODB (19×250mm, 10μm); mobile phase is 40% v / v ACN aqueous solution-0.1% v / v formic acid aqueous solution (1.3:8.7); flow rate 10mL / min; detection wavelength: 210nm, 280nm; column temperature: 30℃; injection volume: 20μl. The results show that under this chromatographic condition, the chromatographic peak separation is good and can be used for preparation and purification. The eluent was collected at the peak time of compound A, and the solvent was recovered under reduced pressure to obtain 7mg of compound A with a purity of >98%.

[0095] Example 4

[0096] This embodiment provides a 3-C-β-D-pyranose glucopyranoside compound, 5-methyl-3-C-β-D-glucopyranoside, and a preparation method thereof.

[0097] The preparation method of compound A specifically comprises the following steps:

[0098] 1. Preparation of crude extract

[0099] Step A: 45 kg of Rhizoma Cynomorii is added with 400 L of water and refluxed for extraction 3 times, each time for 1 hour. Combine the extracts, concentrate under reduced pressure to a specific gravity of 1.10-1.20, add ethanol to a mass concentration of 80%, stand at 4°C for 24 hours, filter, and take the supernatant. The supernatant is concentrated under reduced pressure until there is no alcohol taste, add water to make the volume 20 L, extract with equal volumes of ethyl acetate and n-butanol three times respectively, and then take the aqueous solution;

[0100] Step B, the aqueous solution was fixed to 170 L, and separated using an AB-8 resin column (resin dosage 90 kg), and the separation process was as follows: washing with 5 BV of water and eluting with 5% v / v ethanol, collecting 5% v / v ethanol eluate (10 BV), and removing the solvent under reduced pressure to obtain a dry paste (first dry paste);

[0101] Step C. Separate the first dry paste obtained in step B using a silica gel (200-300 mesh) column. The separation process is as follows: dissolve the first dry paste in dichloromethane, mix it with silica gel in a mass ratio of 1:3, and then evaporate the solvent to dryness. Add it to a silica gel column filled with silica gel (equivalent to 5 times the weight of the dry paste), elute with 2BV ethyl acetate, and remove the solvent under reduced pressure to obtain a dry paste (the second dry paste).

[0102] Step D: Dissolve the second dry paste obtained in step C with methanol, add an equal amount of reverse phase silica gel (YMC GEL, ODS-AQ-HG, S-50 μm) and mix the sample. After evaporating the solvent, separate by reverse phase medium pressure preparative chromatography (filler: YMC GEL, ODS-AQ-HG, S-50 μm; chromatographic column specification: 49×460 mm), and elute with 5% v / v methanol 8VB, 20% v / v methanol 7BV, and 35% v / v methanol 7BV in sequence. Collect the 35% v / v methanol eluate, and remove the solvent under reduced pressure to obtain a crude extract.

[0103] 2. Monomer preparation

[0104] The crude extract was dissolved in 80% v / v methanol aqueous solution, filtered and injected into Waters 1525 semi-preparative liquid chromatograph. The chromatographic conditions were:

[0105] Chromatographic column model: Waters Xterra ODB (19×250mm, 10μm); mobile phase is 70% v / v ACN aqueous solution-water (1.3:8.7); flow rate 10mL / min; detection wavelength: 210nm, 280nm; column temperature: 30℃; injection volume: 20μl. The results show that under this chromatographic condition, the chromatographic peak separation is good and can be used for preparation and purification. The eluent is collected at the peak time of compound A, and the solvent is recovered under reduced pressure to obtain 3mg of compound A with a purity of >98%.

[0106] Example 5

[0107] This embodiment provides a 3-C-β-D-pyranose glucopyranoside compound, 5-methyl-3-C-β-D-glucopyranoside, and a preparation method thereof.

[0108] The preparation method of compound A specifically comprises the following steps:

[0109] 1. Preparation of crude extract

[0110] Step A, add 450L of water to 45kg of Mianma Guanzhong and reflux extract for 3 times, each time for 1 hour. Combine the extracts, concentrate under reduced pressure to a specific gravity of 1.10-1.20, add ethanol to a mass concentration of 80%, stand at 4℃ for 24 hours, filter, and take the supernatant. Concentrate the supernatant under reduced pressure until there is no alcohol taste, add water to make the volume 20L, extract with equal volumes of ethyl acetate and n-butanol three times respectively, and then take the aqueous solution;

[0111] Step B, the aqueous solution was fixed to 160L, and separated using an AB-8 resin column (resin dosage 90kg), and the separation process was as follows: washing with 5BV of water and eluting with 95% v / v ethanol, collecting 95% v / v ethanol eluate (1BV), and removing the solvent under reduced pressure to obtain a dry paste (first dry paste);

[0112] Step C. Separate the first dry paste obtained in step B using a silica gel (200-300 mesh) column. The separation process is as follows: dissolve the first dry paste with methanol-dichloromethane (1:1, v / v), mix it with silica gel in a mass ratio of 1:1, and then evaporate the solvent to dryness, add it to a silica gel column filled with silica gel (equivalent to 50 times the weight of the dry paste), elute with 10BV ethanol, collect the eluate, and remove the solvent under reduced pressure to obtain a dry paste (the second dry paste).

[0113] Step D: Dissolve the second dry paste obtained in step C with methanol, add an equal amount of reversed-phase silica gel (YMC GEL, ODS-AQ-HG, S-50 μm) and mix the sample. After evaporating the solvent, separate the sample by reversed-phase medium-pressure preparative chromatography (filler: YMC GEL, ODS-AQ-HG, S-50 μm; chromatographic column specification: 49×460 mm), and elute with 15% v / v methanol for 3VB, 30% v / v methanol for 5BV, and 50% v / v methanol for 6BV in sequence. Collect the 50% v / v methanol eluate, and remove the solvent under reduced pressure to obtain a crude extract.

[0114] 2. Monomer preparation

[0115] The crude extract was dissolved in 15% v / v methanol aqueous solution, filtered and injected into Waters 1525 semi-preparative liquid chromatograph. The chromatographic conditions were:

[0116] Chromatographic column model: Waters Xterra ODB (19×250mm, 10μm); mobile phase is 90% v / v ACN aqueous solution-0.5% v / v formic acid aqueous solution (1.3:8.7); flow rate 10mL / min; detection wavelength: 210nm, 280nm; column temperature: 30℃; injection volume: 20μl. The results show that under this chromatographic condition, the chromatographic peak separation is good and can be used for preparation and purification. The eluent was collected at the peak time of compound A, and the solvent was recovered under reduced pressure to obtain 4mg of compound A with a purity of >98%.

[0117] Example 6

[0118] In this example, the binding and activity of compound A obtained in Example 1 with 3CL hydrolase were evaluated.

[0119] 1. Activity prediction

[0120] The SDF file of compound A was downloaded from the PubChem database (https: / / pubchem.ncbi.nlm.nih.gov / ) and converted to MOL2 format by Open Babel 2.4.1. The crystal structure of the novel coronavirus (SARS-CoV-2) 3CL hydrolase (PDBID: 7VH8) was downloaded from the PDB database (https: / / www.rcsb.org / ). In addition to the co-crystallized ligand PF-07321332 (nirmatrelvir), three drugs (α-ketoamide, lopinavir, and ritonavir) that have been reported to inhibit 3CL hydrolases were selected as positive controls. The small molecules were energy minimized using PyRx-0.8 software. Ligands and receptors were prepared according to the AutoDock Vina1.1.2 tutorial. For each structure, water molecules were removed, nonpolar hydrogens were added, Gasteiger charges were calculated, and saved in PDBQT format. Generally, the lower the Vina score, the higher the affinity between the ligand and the receptor. The general selection threshold is a binding energy ≤ -5 kcal / mol.Finally, the interaction pattern between compound A and 3CL hydrolase was visualized using Pymol software.

[0121] The results are shown in Table 2.

[0122] Table 2 Docking scores between each compound and 3CL hydrolase

[0123]

[0124] The binding free energies of the above compounds with the 3CL hydrolase target are all lower than -5.0 kJ / mol (a binding free energy less than -5 kcal / mol is considered to have good binding activity. The lower the binding energy, the more stable the ligand-receptor binding conformation), indicating that the ligand and receptor can bind stably.

[0125] In order to dynamically analyze the interaction mode between the receptor 3CL hydrolase and compound A from the perspective of kinetics and thermodynamics, molecular dynamics simulation was performed using GROMACS 4.5 in this example. Protein topology parameters were obtained from the CHARMM36 force field using the PDB2GMX tool. The electrostatic potential of the inhibitor atomic charge was calculated using the Def2-MTZVP basis set of ORCA, and the RESP charge was obtained by fitting using the program Multiwfn 3.7. The complex was placed in a The dodecahedral TIP3P water box was filled with Na +and Cl- to maintain electroneutrality, followed by energy minimization and pre-equilibration. Finally, molecular dynamics simulations were performed at 300 K for 100 ns with a time interval of 2 fs, and energy and coordinate files were saved every 10 ps.

[0126] The results showed that after 35ns of simulation, the root mean square deviation (RMSD) of all systems was 0.1-0.3nm, the fluctuation range was below 0.1nm, and all reached equilibrium.

[0127] By calculating the root mean square fluctuation (RMSF) of the amino backbone atoms in the molecular dynamics simulation of the small molecule and the receptor protein in the complex, this experiment analyzed the effect of compound A on the fluctuation of each amino acid residue in 3CL hydrolase. The study found that the distribution trend of the RMSF value of the complex formed by compound A and 3CL hydrolase obtained in Example 1 is similar to that of PF-07321332 (e.g. Fig. 9 The results show that compound A can form a stable interaction with the binding pocket of 3CL hydrolase and stabilize the amino acid residues therein.

[0128] This experiment extracted the last conformation of the complex after stabilization for 100 nanoseconds of molecular dynamics simulation (e.g. Fig.10 As shown). In order to explore the important role of key groups or amino acid residues in the molecule in the formation of hydrogen bonds, this experiment summarizes the amino acid residues that form hydrogen bonds between 3CL hydrolase and compound A, as shown in Table 3. The results show that the interaction between 3CL hydrolase and the co-crystallized molecule PF-07321332 includes not only hydrogen bonds, but also CH bonds, halogen bonds and alkyl bonds. The interaction between the compound and the amino acid residues is mainly hydrogen bonding. The force of hydrogen bonding reduces the binding energy and increases the affinity. Compound A tightly binds to the active site of 3CL hydrolase to form a stable complex, which can effectively prevent the attachment of foreign viruses and the invasion of host cells.

[0129] PF-07321332 formed three hydrogen bonds with the amino acid residues (Asn142, Glu166 and Gln192) of 3CL hydrolase, indicating that these three amino acid residues may be very important in the drug action process. Compared with the co-crystallized molecule PF-07321332, the sugar ring structure in compound A played a key role in the formation of hydrogen bonds. This experiment found two new amino acid residues, Thr190 and Arg188, which played a key role in the formation of a stable conformation between compound A and 3CL hydrolase, indicating that they may also play an important role in the action of antiviral drugs.

[0130] Table 3 Hydrogen bonds between compounds and 3CL hydrolase

[0131]

[0132] 2. Activity evaluation

[0133] 50 μL of the stock solution of compound A (all 100 mM) was added to a 384-well plate, and then DMSO was added successively to dilute the solution into a series of concentrations, with a total of 10 concentrations. SYSTEM LABCYTE) Transfer 0.2 μL of the diluted solution to a 384-well assay plate, with 2 replicates for each sample. Add 10 μL of 3CL hydrolase (BPSbioscience) working solution to a 384-well plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 15 min. Add 10 μL of substrate working solution and incubate at 25°C for 4 h. Measure the Ex 350nm and Em 460nm fluorescence signals with a microplate reader. Calculate the enzyme activity inhibition rate according to the following formula.

[0134] Inhibition percentage of compound (%inh) = 100 × (ave high control - cpd (compound) well) / (ave high control - ave low control)

[0135] The results showed that the IC of compound A 50 It is 41.53 (mM).

[0136] Example 7

[0137] This embodiment provides an anti-severe acute respiratory syndrome coronavirus type 2 virus drug, the active ingredient of the drug is 3-C-β-D-pyranoglucopyranosyl-5-methylisophthalenedione-6-O-β-D-glucopyranoside obtained in Example 1.

[0138] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. An isophthalic acid compound, It is characterized in that Its structural formula is shown in Formula I:

2. A method for preparing the isophthalic acid compound according to claim 1, It is characterized in that The following steps are involved: Step A, extracting the Rhizoma Cynomorii with water, adding ethanol to the obtained water extract, separating the supernatant after static precipitation, removing alcohol from the supernatant, extracting with ethyl acetate and n-butanol, and collecting the aqueous phase; Step B, separating the aqueous phase by column chromatography using a macroporous resin column: eluting with water and 5-95% v / v ethanol in sequence, collecting the eluate obtained by eluting with 5-95% v / v ethanol, and concentrating it into a dry paste to obtain a first dry paste; Step C, dissolving the first dry paste with an organic solvent, and separating it by column chromatography using a silica gel column: eluting with ethyl acetate, ethanol or a mixture of the two, collecting the obtained eluate, and concentrating it into a dry paste to obtain a second dry paste; Step D: Separate the second dry paste by reverse medium pressure preparative chromatography using reverse phase silica gel: elute with 5-15% v / v methanol, 20-30% v / v methanol, and 35-50% v / v methanol in sequence, collect the eluate obtained by eluting with 35-50% v / v methanol, and concentrate to obtain a crude extract containing the above-mentioned isophthalic acid compounds.

3. The method for preparing the isophthalic acid compound according to claim 2, It is characterized in that In step B, the amount of the eluent is 5 column volumes; and / or In step C, the amount of the eluent is 5 column volumes; and / or In step D, the amount of the eluent used is 5 column volumes.

4. The method for preparing the isophthalic acid compound according to claim 2, It is characterized in that In step B, the macroporous resin in the macroporous resin column is AB-8 resin.

5. The method for preparing the isophthalenedione compound according to any one of claims 2 to 4, It is characterized in that The preparation method also includes dissolving the crude extract in a methanol aqueous solution, separating by semi-preparative high performance liquid chromatography, wherein the mobile phase is a 5% to 95% v / v acetonitrile aqueous solution-0 to 0.5% v / v formic acid aqueous solution in a volume ratio of 1.3:8.7, and isocratic elution.

6. The method for preparing the isophthalic acid compound according to claim 5, It is characterized in that The chromatographic column of the semi-preparative high performance liquid chromatography is octadecyl bonded silica gel; and / or The column temperature of the semi-preparative HPLC method is 25-35°C; and / or The flow rate of the semi-preparative high performance liquid chromatography is 8 to 12 mL / min.

7. The method for preparing the isophthalic acid compound according to claim 6, It is characterized in that The chromatographic column of the semi-preparative HPLC method is a Waters Xterra ODB, with specifications of 19×250 mm, 10 μm; The column temperature of the semi-preparative HPLC method is 30°C; and / or The flow rate of the semi-preparative HPLC was 10 mL / min.

8. Use of the isophthalic acid dione compound according to claim 1 in the preparation of 3CL hydrolase inhibitors.

9. Use of the isophthalic acid dione compound according to claim 1 in the preparation of anti-coronavirus drugs.

10. The use according to claim 9, It is characterized in that The anti-coronavirus drug is an anti-severe acute respiratory syndrome coronavirus type 2 virus drug.